 WATERTOWN, Mass.--BUSINESS WIRE--SQZ Biotechnologies Company NYSE: SQZ, a cell therapy company developing novel treatments for multiple therapeutic areas, will present safety and tolerability, manufacturing, and antitumor activity data from its ongoing Phase 1 clinical trial of SQZ-PBMC-HPV-101 in patients with advanced or metastatic Human Papillomavirus Positive tumors at the 2021 American Society of Clinical Oncology ASCO Annual Meeting, taking place June 4-8. These early data demonstr 